GlassScriptPhysician profile
Sadia J Shafi
NPI 1013178805
$3,772.35
in general payments reported to CMS, 2019-2025
34 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,115 · 2020: $238 · 2021: $14.65 · 2022: $317 · 2023: $613 · 2024: $712 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $505.96 | 2019-2025 | |
| Amgen INC. | $385.46 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $353.50 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $335.49 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $284.67 | 2019-2025 | Farxiga, Breztri |
| Esperion Therapeutics, INC. | $229.16 | 2024-2025 | Nexletol |
| Novo Nordisk INC | $208.97 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.97 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $139.42 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $113.51 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Acadia Pharmaceuticals INC | $111.12 | 2019-2020 | |
| Medtronic Vascular, INC. | $104.97 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.92 | 2022-2023 | Lifevest |
| Pfizer INC. | $73.81 | 2019-2025 | |
| Irhythm Technologies, INC. | $69.86 | 2019-2024 | Zio Xt Patch, Zio Monitor |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $63.91 | 2019 | |
| Avanir Pharmaceuticals, INC. | $62.13 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $42.29 | 2019-2023 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $42.21 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $38.54 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $33.10 | 2019 | |
| Shire North American Group INC | $33.08 | 2019 | |
| Upsher-Smith Laboratories LLC | $32.89 | 2019 | |
| Atricure, INC. | $31.33 | 2024 | |
| Merck Sharp & Dohme LLC | $31.07 | 2022-2023 | Verquvo |
| Amarin Pharma, INC. | $27.63 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $24.52 | 2024 | |
| Acorda Therapeutics, INC | $21.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.60 | 2020 | |
| Corcept Therapeutics | $17.84 | 2019 | |
| Glaxosmithkline, LLC. | $16.48 | 2025 | Shingrix |
| Genzyme Corporation | $14.20 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $13.84 | 2023 | Arcalyst |
| Gilead Sciences, INC. | $13.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadia Shafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.